Your browser doesn't support javascript.
loading
The SUMO conjugating enzyme UBC9 as a biomarker for cervical HPV infections.
Mattoscio, Domenico; Casadio, Chiara; Fumagalli, Marzia; Sideri, Mario; Chiocca, Susanna.
Afiliación
  • Mattoscio D; European Institute of Oncology, Department of Experimental Oncology, Via Adamello 16, 20139 Milan, Italy ; Equally contributed to this work.
  • Casadio C; European Institute of Oncology, Department of Pathology, 20141 Milan, Italy ; Equally contributed to this work.
  • Fumagalli M; TTFactor Srl, Via Adamello 16, 20139 Milan, Italy.
  • Sideri M; European Institute of Oncology, Division of Gynecology, 20141 Milan, Italy.
  • Chiocca S; European Institute of Oncology, Department of Experimental Oncology, Via Adamello 16, 20139 Milan, Italy.
Ecancermedicalscience ; 9: 534, 2015.
Article en En | MEDLINE | ID: mdl-26015803
ABSTRACT
Human papillomaviruses (HPVs) infect stratified epithelium and are the causative agents of cervical cancer, the second most common cause of cancer-related death in women. A critical aspect that still persists in the HPV field is the selection of very sensitive and specific HPV diagnostic assays. Here, we provide evidence that the crucial small ubiquitin-like modifier (SUMO) E2-conjugating enzyme Ubc9 is strongly upregulated in cervical lesions. Ubc9 detection could thus be used in diagnosing and/or monitoring the progression of an HPV oncogenic infection.
Palabras clave

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Ecancermedicalscience Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Ecancermedicalscience Año: 2015 Tipo del documento: Article